专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012126427A3 LASER WITH TUNABLE OUTER CAVITY AND METHOD FOR USING SAME 审中-公开
标题翻译：具有可控外腔的激光器及其使用方法
公开(公告)号：WO2012126427A3
公开(公告)日：2013-04-18
申请号：PCT/CN2012075816
申请日：2012-05-21
申请人： HUAWEI TECH CO LTD , CHEN BO , GAO LEI , ZHANG GUANGYONG , CHEN XI
发明人： CHEN BO , GAO LEI , ZHANG GUANGYONG , CHEN XI
IPC分类号： H01S5/14 , H01S3/10 , H01S3/13 , H01S3/139
CPC分类号： H01S5/141
摘要： A laser with tunable outer cavity and a method for using same, said laser with tunable outer cavity comprising a gain chip (100), a collimating mirror (200), a wavelength selection element (300), and an optical path for the generation of an optical path difference (400). A cavity surface (1002) of the gain chip is located in a focal plane of the collimating mirror. The wavelength selection element is located between the collimating mirror and the optical path for the generation of an optical path difference. Light beams emitted from the cavity surface of the gain chip are collimated by the collimating mirror to form parallel beams which are sent to the wavelength selection element; the wavelength selection element filters the parallel beams from the collimating mirror and then sends them to the optical path for the generation of an optical path difference. The optical path for the generation of an optical path difference splits the parallel beams entering same into at least two branch beams, and reflects each of said branch beams to the gain chip according to the incident direction. The optical path for the generation of an optical path difference is able to adjust the optical path difference between the optical paths of the branch beams. Since the optical path for the generation of an optical path difference serves to roughly select a mode, there is no need for precise control of adjustment and the process of wavelength tuning and selection is made easier.
摘要翻译：一种具有可调外腔的激光器及其使用方法，所述具有可调谐外腔的激光器包括增益芯片（100），准直镜（200），波长选择元件（300）和用于产生光路差（400）。增益芯片的空腔表面（1002）位于准直镜的焦平面中。波长选择元件位于准直镜和用于产生光程差的光路之间。从增益芯片的空腔表面发射的光束被准直镜准直，以形成被发送到波长选择元件的平行光束; 波长选择元件对来自准直镜的平行光束进行滤波，然后将它们发送到光路以产生光程差。用于产生光路差的光路将入射到其的平行光束分成至少两个分支光束，并根据入射方向将每个所述分支光束反射到增益芯片。用于产生光程差的光路能够调整分支光束的光路之间的光程差。由于用于产生光程差的光路用于粗略地选择模式，所以不需要精确的调整控制，并且使波长调谐和选择的处理变得更容易。

2. 发明申请

WO2013013244A3 CHEMOENZYMATIC SYNTHESIS OF HEPARIN AND HAPARAN SULFATE ANALOGS 审中-公开
标题翻译：胡椒碱和海参硫酸酯类似物的化学合成
公开(公告)号：WO2013013244A3
公开(公告)日：2013-07-11
申请号：PCT/US2012047875
申请日：2012-07-23
申请人： UNIV CALIFORNIA , CHEN XI , YU HAI , LI YANHONG , CHEN YI , QU JINGYAO , MUTHANA MUSLEH M
发明人： CHEN XI , YU HAI , LI YANHONG , CHEN YI , QU JINGYAO , MUTHANA MUSLEH M
IPC分类号： C12P19/04 , C07H3/06 , C08B37/10 , C12N9/04 , C12N9/12
CPC分类号： C07H1/00 , C07H13/04 , C08B37/0075 , C12P19/04 , C12P19/12 , C12P19/18 , C12P19/305 , C12P19/44
摘要： The present invention provides a one-pot, multi-enzyme method for preparing UDP-sugars from simple sugar starting materials. The invention also provides a one-pot, multi-enzyme method for preparing oligosaccharides from simple sugar starting materials.
摘要翻译：本发明提供了从单糖原料制备UDP-糖的一锅多酶方法。本发明还提供了从单糖原料制备寡糖的一锅多酶方法。

3. 发明申请

WO2006053323A3 INHIBITORS OF HIV-1 CAPSID FORMATION: SUBSTITUTED ARYL AMINOMETHYL THIAZOLE UREAS AND ANALOGUES THEREOF 审中-公开
标题翻译： HIV-1壳体形成的抑制剂：取代的芳基胺甲基噻唑尿素及其类似物
公开(公告)号：WO2006053323A3
公开(公告)日：2006-08-24
申请号：PCT/US2005041358
申请日：2005-11-10
申请人： ACHILLION PHARMACEUTICALS INC , UNIV MARYLAND , AGARWAL ATUL , CHEN XI , DESHPANDE MILIND , SUMMERS MICHAEL
发明人： AGARWAL ATUL , CHEN XI , DESHPANDE MILIND , SUMMERS MICHAEL
IPC分类号： A61P31/12 , A61K31/381 , A61K31/426 , A61K31/4353
CPC分类号： C07D471/04 , C07D263/48 , C07D277/40 , C07D277/48 , C07D401/06 , C07D417/06 , C07D417/12 , C07D495/04 , C07D513/04
摘要： Substituted aryl aminomethyl thiazole ureas and analogues thereof that act as inhibitors of viral capsid formation, including HIV capsid formation, are provided here. Generally the virus capsid formation inhibitors described herein are compounds of Formula (I) where A is a group of formula (a) or (b) wherein the variables A, R 1 , R 2 , R 3 , R 4 , X, Y, Z, A 5 , A 6 , A 7 , R 8 , R 9 , R 12 , and R 13 are defined herein. Pharmaceutical compositions comprising such compounds and methods of treating animals infected with a virus having a capsid protein are provided herein. Methods of using such compounds to treat human patients infected with an HIV virus and reducing the mortality of AIDS are also provided herein.
摘要翻译：这里提供了作为病毒衣壳形成抑制剂（包括HIV衣壳形成）的取代的芳基氨基甲基噻唑脲及其类似物。通常，本文所述的病毒衣壳形成抑制剂是式（I）的化合物，其中A是式（a）或（b）的基团，其中变量A，R 1，R 2， / SUB>，SUB <3>，_{4 _{，X，Y，Z，_{5 ，_{6 ， A <7>，_{8 ，R _{9 ，R _{12 和R _{13 在此定义。本文提供了包含此类化合物的药物组合物以及治疗感染了具有衣壳蛋白的病毒的动物的方法。本文还提供了使用这些化合物来治疗感染HIV病毒的人类患者并降低AIDS的死亡率的方法。}}}}}}}}

4. 发明申请

WO2013152317A3 NITRITE TRANSPORTER AND METHODS OF USING THE SAME 审中-公开
标题翻译：亚硝酸盐转运器及其使用方法
公开(公告)号：WO2013152317A3
公开(公告)日：2013-12-12
申请号：PCT/US2013035500
申请日：2013-04-05
申请人： SYNGENTA PARTICIPATIONS AG , UNIV GUELPH , LISERON-MONFILS CHRISTOPHE , ZHU TONG , SKALLA DALE , BORTIRI ESTEBAN , BI YONG-MEI , DOWNS GREGORY , LUKENS LEWIS N , COLASANTI JOSEPH , ROTHSTEIN STEVEN , RAIZADA MANISH , CHEN XI
发明人： LISERON-MONFILS CHRISTOPHE , ZHU TONG , SKALLA DALE , BORTIRI ESTEBAN , BI YONG-MEI , DOWNS GREGORY , LUKENS LEWIS N , COLASANTI JOSEPH , ROTHSTEIN STEVEN , RAIZADA MANISH , CHEN XI
IPC分类号： A01H1/06 , C12N15/10 , C12N15/82
CPC分类号： C07K14/415 , C12N15/8261 , Y02A40/146
摘要： The invention generally relates to a nitrite transporter and methods of using the same.
摘要翻译：本发明总体上涉及亚硝酸盐转运蛋白及其使用方法。

5. 发明申请

WO2009060312A8 STRUCTURED SOAP COMPOSITIONS 审中-公开
标题翻译：结构化的肥皂组合物
公开(公告)号：WO2009060312A8
公开(公告)日：2010-02-18
申请号：PCT/IB2008003759
申请日：2008-08-15
申请人： RHODIA ASIA PACIFIC PTE LTD , CHEN XI , SEOW SWEE-HOW , FUETTERER TOBIAS
发明人： CHEN XI , SEOW SWEE-HOW , FUETTERER TOBIAS
IPC分类号： C11D17/00 , C11D9/26 , C11D10/04
CPC分类号： C11D17/0026 , C11D1/52 , C11D1/667 , C11D1/72 , C11D9/26 , C11D9/267 , C11D10/04 , C11D10/045 , C11D10/047
摘要： A structured soap composition contains, based on 100 parts by weight of said composition, (i) from greater than 0 to about 27 parts by weight of a neutralized fatty acid, (ii) from greater than 0 to about 18 parts by weight of one or more structurant selected from alkanolamide surfactants, fatty alcohols, alkoxylated fatty alcohols, fatty acids, and fatty acid esters, (iii) from 0 to about 15 parts by weight of one or more compounds selected from amphoteric surfactants and zwitterionic surfactants, provided that the total amount of components (i), (ii), and (iii) is greater than or equal to 5 parts by weight, (iv) an amount of electrolyte effective to, in combination with components (i), (ii), and (iii) provide a structured soap composition having an opaque visual appearance and exhibiting a yield strength of greater than 0 Pascals, and (v) water.
摘要翻译：结构化皂组合物基于100重量份的所述组合物含有（i）大于0至约27重量份的中和的脂肪酸，（ii）大于0至约18重量份的一种或更多选自烷醇酰胺表面活性剂，脂肪醇，烷氧基化脂肪醇，脂肪酸和脂肪酸酯的结构化剂，（iii）0至约15重量份的一种或多种选自两性表面活性剂和两性离子表面活性剂的化合物，条件是组分（i），（ii）和（iii）的总量大于或等于5重量份，（iv）与组分（i），（ii）和（iii）提供具有不透明视觉外观并且表现出大于0帕斯卡的屈服强度的结构化皂组合物，和（v）水。

6. 发明申请

WO2005121331A8 TRUNCATED GALNACT2 POLYPEPTIDES AND NUCLEIC ACIDS 审中-公开
标题翻译：截短的GALNACT2多肽和核酸
公开(公告)号：WO2005121331A8
公开(公告)日：2006-03-09
申请号：PCT/US2005019442
申请日：2005-06-03
申请人： NEOSE TECHNOLOGIES INC , JOHNSON KARL F , CHEN XI , TAUDTE SUSANN , SARIBAS SAMI
发明人： JOHNSON KARL F , CHEN XI , TAUDTE SUSANN , SARIBAS SAMI
IPC分类号： C12N9/10
CPC分类号： C12N9/1051
摘要： The present invention features compositions and methods related to truncated mutants of GalNAcT2. In particular, the invention features truncated human GalNAcT2 polypeptides. The invention also features nucleic acids encoding such truncated polypeptides, as well as vectors, host cells, expression systems, and methods of expressing and using such polypeptides.
摘要翻译：本发明的特征在于与GalNAcT2的截短突变体相关的组合物和方法。特别地，本发明特征在于截短的人GalNAcT2多肽。本发明还包括编码这种截短的多肽的核酸，以及载体，宿主细胞，表达系统以及表达和使用这些多肽的方法。

7. 发明申请

WO2005095345A3 HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION 审中-公开
标题翻译：作为病毒复制抑制剂的异氟烷类药物
公开(公告)号：WO2005095345A3
公开(公告)日：2005-12-01
申请号：PCT/US2005009710
申请日：2005-03-23
申请人： ACHILLION PHARMACEUTICALS INC , CHEN XI , LIU CIUXAN , THURKAUF ANDREW , LOUISE-MAY SHIRLEY
发明人： CHEN XI , LIU CIUXAN , THURKAUF ANDREW , LOUISE-MAY SHIRLEY
IPC分类号： A61K31/44 , A61K31/505 , A61K31/517 , C07C279/18 , C07D213/75 , C07D213/82 , C07D239/54 , C07D239/545 , C07D239/84 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D417/12 , A61P31/14
CPC分类号： C07C279/18 , C07D213/75 , C07D213/82 , C07D239/42 , C07D239/47 , C07D239/545 , C07D239/84 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
摘要： Compounds of Formula (1), and pharmaceutically acceptable forms thereof, are provided wherein the variables X, Y, Z, Al, R2, R3, R4, R5 and R6 are defined herein. Certain compounds of Formula 1 described herein which possess potent antiviral activity. Certain compounds of Formula (1) that are potent and/ or selective inhibitors of Hepatitis C virus replication. Pharmaceutical compositions containing one or more compounds of Formula (1), or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents are also provided. Methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound of Formula (1) effective to reduce signs or symptoms of the disease or disorder are disclosed. These infectious diseases include viral infections, particularly HCV infections. Methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound of Formula (1) as a single active agent or administering a compound of Formula (1) in combination with on or more other therapeutic agent.
摘要翻译：提供式（1）的化合物及其药学上可接受的形式，其中变量X，Y，Z，Al，R 2，R 3，R 4，R 5和R 6在本文中定义。某些本文所述的具有强抗病毒活性的式1的化合物。某些式（1）化合物是丙型肝炎病毒复制的有效和/或选择性抑制剂。还提供了含有一种或多种式（1）化合物或这些化合物的盐，溶剂化物或酰化前药以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。公开了通过向这些患者施用一定量的有效减少疾病或病症的体征或症状的式（1）化合物来治疗患有某些感染性疾病的患者的方法。这些传染病包括病毒感染，特别是HCV感染。治疗患有感染性疾病的人类患者的方法，还包括治疗其他动物，包括患有传染病的家畜和驯养的伴侣动物的方法。治疗方法包括施用作为单一活性剂的式（1）化合物或将式（1）的化合物与一种或多种其它治疗剂组合施用。

8. 发明申请

WO0012500A3 2-ARYL-4-(1-[4-HETEROARYL]PIPERAZIN-1-YL) METHYLIMIDAZOLES: DOPAMINE D4 RECEPTOR SUBTYPE LIGANDS 审中-公开
标题翻译： 2-亚氨基-4-（1- [4-异丙基]哌嗪-1-基）甲基咪唑烷酮：DOPAMINE D4受体亚型配体
公开(公告)号：WO0012500A3
公开(公告)日：2000-07-27
申请号：PCT/US9920176
申请日：1999-09-02
申请人： NEUROGEN CORP , CHEN XI , THURKAUF ANDREW
发明人： CHEN XI , THURKAUF ANDREW
IPC分类号： C07D215/38 , C07D239/84 , C07D241/44 , C07D401/12 , C07D403/12 , A61K31/47
CPC分类号： C07D215/38 , C07D239/84 , C07D241/44 , C07D401/12 , C07D403/12
摘要： Disclosed are compounds of formula: (I) or the pharmaceutically acceptable acid addition salts thereof wherein Ra represents (II) where X, Y and Z are the same or different and represent CH or nitrogen; R1, R2, R3 and R4 independently represent organic or inorganic groups: and R5 is hydrogen, C1-C6 alkyl or halogen, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behaviour, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.
摘要翻译：公开了式（I）化合物或其药学上可接受的酸加成盐，其中R a表示（II），其中X，Y和Z相同或不同，表示CH或氮; R1，R2，R3和R4独立地表示有机或无机基团：R5是氢，C1-C6烷基或卤素，该化合物可用于治疗和/或预防神经心理障碍，包括但不限于精神分裂症，躁狂症，痴呆，抑郁，焦虑，强迫行为，药物滥用，帕金森氏样运动障碍和与使用精神安定药有关的运动障碍。

9. 发明申请

WO2012030911A3 POWERED MOBILITY SYSTEMS AND METHODS 审中-公开
标题翻译：动力移动系统和方法
公开(公告)号：WO2012030911A3
公开(公告)日：2012-06-28
申请号：PCT/US2011049891
申请日：2011-08-31
申请人： UNIV DELAWARE , AGRAWAL SUNIL K , GALLOWAY JAMES C , CHEN XI , RAGONESI CHRISTINA B , LIANG SHERRY , DOLPH STEPHEN , SCHOEPFLIN ZACHARY R
发明人： AGRAWAL SUNIL K , GALLOWAY JAMES C , CHEN XI , RAGONESI CHRISTINA B , LIANG SHERRY , DOLPH STEPHEN , SCHOEPFLIN ZACHARY R
IPC分类号： A47D13/02 , A47D15/00
CPC分类号： A61G5/04 , A61F5/0102 , A61G2200/14 , A61G2200/325 , A61G2200/34 , A61G2203/10 , A61G2203/36
摘要： Powered mobility systems and methods are disclosed. A powered mobility system includes a mobile unit, a support frame, a plurality of markers, a motion capture device, and a processor. The mobile unit is operable to move the powered mobility system. The support frame is adapted to support a user. The plurality of markers are configured to be attached to the user. The motion capture device is configured to detect movement of the plurality of markers. The processor is programmed to receive signals from the motion capture device, translate the signals into instructions for moving the mobile unit, and transmit the instructions to the mobile unit. A powered mobility method includes placing a user in a support frame, attaching a plurality of markers to the user, detecting movement of the plurality of the markers, and generating movement of the mobile unit based on the movement of the plurality of the markers.
摘要翻译：公开了动力移动系统和方法。动力移动系统包括移动单元，支撑框架，多个标记，运动捕捉设备和处理器。移动单元可操作以移动动力移动系统。支撑框架适于支持用户。多个标记被配置为附接到用户。运动捕捉装置被配置为检测多个标记的移动。处理器被编程为从运动捕获装置接收信号，将信号转换成用于移动移动单元的指令，并将指令发送到移动单元。动力移动方法包括将用户放置在支撑框架中，将多个标记附接到使用者，检测多个标记的移动，以及基于多个标记的移动来产生移动单元的移动。

10. 发明申请

WO2010091373A3 TRIMERICH HIV FUSION INHIBITORS FOR TREATING OR PREVENTING HIV INFECTION 审中-公开
标题翻译： TRIMERICH艾滋病毒融合抑制剂治疗或预防艾滋病毒感染
公开(公告)号：WO2010091373A3
公开(公告)日：2010-09-30
申请号：PCT/US2010023522
申请日：2010-02-08
申请人： NEW YORK BLOOD CT INC , JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
发明人： JIANG SHIBO , QI ZHI , CHEN XI , PAN CHUNGEN
IPC分类号： A61K38/17 , A61P31/18
CPC分类号： A61K38/162 , A61K38/00 , C07K14/005 , C07K2319/735 , C12N7/00 , C12N2740/16022 , C12N2740/16033 , C12N2740/16111 , C12N2740/16122
摘要： Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1 ) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
摘要翻译：本文公开了包含三种单体的三聚体多肽药物组合物，每种单体包含具有人类跨膜糖蛋白的N-末端七肽重复（NHR或HR1）或C-末端七重复重复（CHR或HR2）的氨基酸序列的多肽免疫缺陷病毒（HIV）和三聚体基序。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式